Review



deming linear regression graphpad prism 7.00  (GraphPad Software Inc)


Bioz Verified Symbol GraphPad Software Inc is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    GraphPad Software Inc deming linear regression graphpad prism 7.00
    Detection of adalimumab and infliximab with the bioluminescence reader. Luminescence over time with (a) infliximab dRAPPID or (b) adalimumab dRAPPID sensor (10 nM LB with 20 nM SB). Blue-to-green ratios of (c) infliximab and (d) adalimumab captured with the reader (15 minutes of incubation) in buffer. Detection of (e) infliximab and (f) adalimumab in patient serum samples with dRAPPID in combination with the bioluminescence reader. The black lines in (e) and (f) represent <t>Deming</t> <t>linear</t> regression. Vertical dotted lines connects duplicate measurements of one patient sample. Values in (a) and (b) depict mean ± s.d. of technical replicates and data points in (c) and (d) represent technical replicates, with n = 3 independent preparations of target antibody.
    Deming Linear Regression Graphpad Prism 7.00, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/deming linear regression graphpad prism 7.00/product/GraphPad Software Inc
    Average 90 stars, based on 1 article reviews
    deming linear regression graphpad prism 7.00 - by Bioz Stars, 2026-06
    90/100 stars

    Images

    1) Product Images from "Point-of-care therapeutic drug monitoring of tumour necrosis factor-α inhibitors using a single step immunoassay † "

    Article Title: Point-of-care therapeutic drug monitoring of tumour necrosis factor-α inhibitors using a single step immunoassay †

    Journal: Sensors & Diagnostics

    doi: 10.1039/d3sd00131h

    Detection of adalimumab and infliximab with the bioluminescence reader. Luminescence over time with (a) infliximab dRAPPID or (b) adalimumab dRAPPID sensor (10 nM LB with 20 nM SB). Blue-to-green ratios of (c) infliximab and (d) adalimumab captured with the reader (15 minutes of incubation) in buffer. Detection of (e) infliximab and (f) adalimumab in patient serum samples with dRAPPID in combination with the bioluminescence reader. The black lines in (e) and (f) represent Deming linear regression. Vertical dotted lines connects duplicate measurements of one patient sample. Values in (a) and (b) depict mean ± s.d. of technical replicates and data points in (c) and (d) represent technical replicates, with n = 3 independent preparations of target antibody.
    Figure Legend Snippet: Detection of adalimumab and infliximab with the bioluminescence reader. Luminescence over time with (a) infliximab dRAPPID or (b) adalimumab dRAPPID sensor (10 nM LB with 20 nM SB). Blue-to-green ratios of (c) infliximab and (d) adalimumab captured with the reader (15 minutes of incubation) in buffer. Detection of (e) infliximab and (f) adalimumab in patient serum samples with dRAPPID in combination with the bioluminescence reader. The black lines in (e) and (f) represent Deming linear regression. Vertical dotted lines connects duplicate measurements of one patient sample. Values in (a) and (b) depict mean ± s.d. of technical replicates and data points in (c) and (d) represent technical replicates, with n = 3 independent preparations of target antibody.

    Techniques Used: Incubation



    Similar Products

    deming linear regression graphpad prism 7.00  (GraphPad Software Inc)
    90
    GraphPad Software Inc deming linear regression graphpad prism 7.00
    Detection of adalimumab and infliximab with the bioluminescence reader. Luminescence over time with (a) infliximab dRAPPID or (b) adalimumab dRAPPID sensor (10 nM LB with 20 nM SB). Blue-to-green ratios of (c) infliximab and (d) adalimumab captured with the reader (15 minutes of incubation) in buffer. Detection of (e) infliximab and (f) adalimumab in patient serum samples with dRAPPID in combination with the bioluminescence reader. The black lines in (e) and (f) represent <t>Deming</t> <t>linear</t> regression. Vertical dotted lines connects duplicate measurements of one patient sample. Values in (a) and (b) depict mean ± s.d. of technical replicates and data points in (c) and (d) represent technical replicates, with n = 3 independent preparations of target antibody.
    Deming Linear Regression Graphpad Prism 7.00, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/deming linear regression graphpad prism 7.00/product/GraphPad Software Inc
    Average 90 stars, based on 1 article reviews
    deming linear regression graphpad prism 7.00 - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Detection of adalimumab and infliximab with the bioluminescence reader. Luminescence over time with (a) infliximab dRAPPID or (b) adalimumab dRAPPID sensor (10 nM LB with 20 nM SB). Blue-to-green ratios of (c) infliximab and (d) adalimumab captured with the reader (15 minutes of incubation) in buffer. Detection of (e) infliximab and (f) adalimumab in patient serum samples with dRAPPID in combination with the bioluminescence reader. The black lines in (e) and (f) represent Deming linear regression. Vertical dotted lines connects duplicate measurements of one patient sample. Values in (a) and (b) depict mean ± s.d. of technical replicates and data points in (c) and (d) represent technical replicates, with n = 3 independent preparations of target antibody.

    Journal: Sensors & Diagnostics

    Article Title: Point-of-care therapeutic drug monitoring of tumour necrosis factor-α inhibitors using a single step immunoassay †

    doi: 10.1039/d3sd00131h

    Figure Lengend Snippet: Detection of adalimumab and infliximab with the bioluminescence reader. Luminescence over time with (a) infliximab dRAPPID or (b) adalimumab dRAPPID sensor (10 nM LB with 20 nM SB). Blue-to-green ratios of (c) infliximab and (d) adalimumab captured with the reader (15 minutes of incubation) in buffer. Detection of (e) infliximab and (f) adalimumab in patient serum samples with dRAPPID in combination with the bioluminescence reader. The black lines in (e) and (f) represent Deming linear regression. Vertical dotted lines connects duplicate measurements of one patient sample. Values in (a) and (b) depict mean ± s.d. of technical replicates and data points in (c) and (d) represent technical replicates, with n = 3 independent preparations of target antibody.

    Article Snippet: Deming linear regression (GraphPad Prism 7.00) was applied to determine the relationship between the mean results with the bioluminescence reader dRAPPID and the ELISA.

    Techniques: Incubation